US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 20:29:06 Source:sportViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
You may also like
- FDIC chairman Martin Gruenberg to step down, White House says
- 911 emergency lines go DOWN across multiple states including South Dakota and Nebraska
- Dumb, dumber and dumbest! Idiot thieves steal van and take their masks off
- IDF forces are accused of beating and torturing captured Palestinians
- Britain's new bonkers EV: Callum Skye is an £80k electric buggy built in Warwickshire
- Juventus ordered to pay Ronaldo more than $10 million in salary dispute
- Powerful 6.3
- Tesla's Cybertruck disaster: Insider reveals 'serious safety issues' behind scenes of EV rollout
- Strictly star Giovanni Pernice's former partner Rose Ayling